The goal of treatment for patients with unresectable Stage 3 NSCLC is curative intent1

Stage 3 NSCLC has a distinct clinical presentation from metastatic (Stage 4) disease and has different treatment goals2-4

24% of patients with NSCLC present with Stage 3 disease

~24% of patients with NSCLC present with Stage 3 disease5


~82% of patients with Stage 3 NSCLC have unresected disease6*


Treatment with curative intent concurrent chemoradiotherapy is given to patients and offers patients additional treatment options in the unresectable Stage 3 NSCLC setting7

Dr. Kristin Higgins image

Dr. Kristin Higgins imageHear Dr Kristin Higgins discuss these real patients with Stage 3A, B, or C NSCLC treated with curative intent concurrent CRT

Real Patient Case 1
Diagnosis: Unresectable Stage 3A NSCLC (T4N0)
Real Patient Case 2
Diagnosis: Unresectable Stage 3B NSCLC (T1cN3M0)
Real Patient Case 3
Diagnosis: Unresectable Stage 3C NSCLC (T4N3M0)

Hear from multidisciplinary experts about treating with curative intent CRT

What may be untreatable yesterday is treatable today...Stage III lung cancer is a curative disease. So we should maximize [the] chance of a cure...

–Dr Kristin Higgins & Dr Joe Chang

NSCLC=non-small cell lung cancer; CRT=chemoradiotherapy.

*Unresected disease includes patients with unresectable disease and patients with resectable disease who declined surgical intervention.

These videos contain details of a real patient and physician’s experience treating this patient and do not represent the views or opinions of AstraZeneca. Individual experiences and recommendations may vary with patients.

The views and opinions expressed in the Art of CRT video series are those of the individual panel members and do not represent the views or opinions of AstraZeneca. These videos contain anecdotal information gathered from a discussion with 8 physicians and nurses based on their opinions/experiences. Recommendations are general and may vary with patients.

References: 1. Cheema PK, Rothenstein J, Melosky B, Brade A, Hirsh V. Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer. Curr Oncol. 2019;26(1):37-42. 2. Rami-Porta R, Asamura H, Travis WD, Rusch VW. Lung cancer—major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(2):138-155. 3. Lung cancer—non-small cell: stages. Cancer.Net website. Accessed March 3, 2020. 4. Robinson AG, Young K, Balchin K, Owen T, Ashworth A. Reasons for palliative treatments in stage III non-small-cell lung cancer: what contribution is made by time-dependent changes in tumour or patient status? Curr Oncol. 2015;22(6):399-404. 5. EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2025. New York, NY: GlobalData; November 2016. 6. Kantar Health CancerMPact. Treatment modality. Accessed July 20, 2020. 7. Moore S, Leung B, Wu J, Ho C. Real-world treatment of stage III NSCLC: the role of trimodality treatment in the era of immunotherapy. J Thorac Oncol. 2019;14(8):1430-1439.